One product is mRNA-2416, using mRNA encoding OX40L, either dosed alone or in combination with IV administered PD-L1 inhibitor durvalumab for treatment of lymphoma and metastatic ovarian cancer (NCT03323398) [639]. Here, TNFSF4 is linked to lymphoma.